<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03753776</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0601</org_study_id>
    <secondary_id>2018-002406-32</secondary_id>
    <nct_id>NCT03753776</nct_id>
  </id_info>
  <brief_title>Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women</brief_title>
  <acronym>HOMEORAD</acronym>
  <official_title>Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the second most frequent cancer worldwide. Principal therapy consists in
      radiotherapy, but this technic has sides effects as radiodermatitis, concerning about 90
      percent of women treated.

      Risk of flushing could be reduced by hygienic rules, but no treatment proved its efficacy to
      prevent radiodermatitis.

      Homeopathy is popular but also contested. No clinical trial proved its efficacy for this
      indication. The present study aims at evaluating Radium bromatum efficacy (homeopathy),
      compared to placebo, to prevent radiodermatitis apparition for women treated for breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the second most frequent cancer worldwide, and the most frequent in France.
      Principal therapy consists in radiotherapy, that is locoregional, using radiations to kill
      cancerous cells.

      Radiotherapy has sides effects as radiodermatitis, concerning about 90 percent of women
      treated. Radiodermatitis could be described with three factors : redness, heat, and edema.

      Risk of flushing could be reduced by hygienic rules concerning hydratation, clothes, and
      toilet.

      Nowadays, no treatment proved homeopathic efficacy to prevent radiodermatitis. This treatment
      is popular but also contested. No clinical trial proved its efficacy for this indication. The
      present study aims at evaluating Radium bromatum efficacy (homeopathy), compared to placebo,
      to prevent radiodermatitis apparition for women treated for breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A first randomization will establish two groups : placebo versus homeopathy (Radium bromatum), and if patients develop a radiodermatitis of grade 2 or higher, a second randomization will take place, with two groups : placebo versus homeopathy (Radium bromatum, Apis mellifica, and Belladonna)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Neither patients receiving pills nor doctors evaluating radiodermatitis know the nature of treatment (placebo or homeopathy)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage diminution of grade 2 or higher radiodermatitis in Radium bromatum group</measure>
    <time_frame>Week 6</time_frame>
    <description>Percentage diminution of grade 2 or higher radiodermatitis in Radium bromatum group will be measure with the RTOG (Radiation Therapy Oncology Group) scale. A diminution of 10% between Radium bromatum group and placebo group will be considered as significant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiodermatitis frequency</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of Radiodermatitis according to the RTOG (Radiation Therapy Oncology Group) scale will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiodermatitis duration</measure>
    <time_frame>Week 6</time_frame>
    <description>Radiodermatitis duration will be reported in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiodermatitis delays</measure>
    <time_frame>Week 6</time_frame>
    <description>Radiodermatitis delays will be reported in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of concomitant treatments</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of concomitant treatments will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain measure</measure>
    <time_frame>Week 6</time_frame>
    <description>Measure of pain will be reported, calculated with a oral scale between 0 and 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Quality of life</measure>
    <time_frame>Week 6</time_frame>
    <description>Level of Quality of life will be measured between 0 to 100 with the EQ-5D questionnaire (european quality of life number 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction measure</measure>
    <time_frame>Week 6</time_frame>
    <description>Satisfaction will be measured with a oral scale between 0 (no satisfaction) and 3 (full satisfaction)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Radium bromatum placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group will receive placebo pills of Radium bromatum during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium bromatum group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium bromatum/Apis mellifica/Belladonna placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium bromatum/Apis mellifica/Belladonna group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pills of Radium bromatum</intervention_name>
    <description>Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition</description>
    <arm_group_label>Radium bromatum placebo group</arm_group_label>
    <other_name>Radium bromatum placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium bromatum pills</intervention_name>
    <description>Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition</description>
    <arm_group_label>Radium bromatum group</arm_group_label>
    <other_name>Radium bromatum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium bromatum/Apis mellifica/Belladonna placebo pills</intervention_name>
    <description>Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation</description>
    <arm_group_label>Radium bromatum/Apis mellifica/Belladonna placebo group</arm_group_label>
    <other_name>Radium bromatum/Apis mellifica/Belladonna placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium bromatum/Apis mellifica/Belladonna pills</intervention_name>
    <description>Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation</description>
    <arm_group_label>Radium bromatum/Apis mellifica/Belladonna group</arm_group_label>
    <other_name>Radium bromatum/Apis mellifica/Belladonna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patient;

          -  Indication of curative intent radiotherapy for breast cancer treated with conservative
             treatment. Accepted radiotherapy scheme: 50 Gy (main) + 16 Gy on the tumor bed
             (additional dose);

          -  Patient affiliated or entitled to a social security scheme;

          -  Patient who signed an informed consent form.

        Exclusion Criteria:

          -  Pregnant or lactating woman;

          -  Legal incapacity or limited legal capacity. Medical or psychological conditions that
             do not allow the subject to understand the study and sign the consent

          -  Patient followed by a liberal homeopath;

          -  Patient with bilateral breast cancer;

          -  Patient with in situ breast cancer;

          -  Patient with known cognitive impairment;

          -  Patient with known allergy and / or intolerance and / or malabsorption to fructose,
             glucose, galactose;

          -  Patient with a known deficiency in sucrase / isomaltase / lactase.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélie Beneton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie Beneton, MD</last_name>
    <phone>0477917136</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelie.beneton@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde Gras, MsC</last_name>
    <phone>0477917136</phone>
    <phone_ext>+33</phone_ext>
    <email>mathilde.gras@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Beneton, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie Beneton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie Morisson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle Brosse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Magné, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amel Rehailia-Blanchard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane-Chloé Trone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Baptiste Guy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Langrand-Escure, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Homeopathy</keyword>
  <keyword>Radium bromatum</keyword>
  <keyword>Apis mellifica</keyword>
  <keyword>Belladonna</keyword>
  <keyword>Radiodermatitis</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Prevention</keyword>
  <keyword>Treatment</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

